Serina Therapeutics, Inc. is a privately-held pharmaceutical company that is advancing novel therapeutics for Parkinson’s disease, restless leg syndrome, cancer, epilepsy, inflammation and pain using its proprietary, patented polymer technology. The company has created new pharmaceutical candidates using polyoxazoline (POZ) – a safe, water-soluble polymer to which a variety of small molecules, proteins, peptides and DNA can be attached. This attachment confers a unique pharmacokinetic profile that is markedly different from the parent compound. This profile may confer advantages in terms of safety and efficacy. In general, molecules attached to POZ stay in the body for a much longer period of time – and can be precisely tuned to achieve the desired therapeutic profile. In addition to progressing its CNS-focused pipeline, Serina Therapeutics has partnered its technology with two of the top ten pharmaceutical companies worldwide, and is actively seeking new partnerships.

Randall W. Moreadith, MD, PhD
President & Chief
Executive Officer

Tacey X. Viegas, PhD
Chief Operating Officer

Mike D. Bentley, PhD
Chief Scientific Officer

J. Milton Harris, PhD

All resident associate companies on the HudsonAlpha campus are independently owned and operated.